LAB
Price
$1.82
Change
-$0.08 (-4.21%)
Updated
Dec 27, 04:59 PM (EDT)
47 days until earnings call
NDRA
Price
$6.54
Change
+$1.00 (+18.05%)
Updated
Dec 27, 04:00 PM (EDT)
Ad is loading...

LAB vs NDRA

Header iconLAB vs NDRA Comparison
Open Charts LAB vs NDRABanner chart's image
Standard BioTools
Price$1.82
Change-$0.08 (-4.21%)
Volume$9.31K
CapitalizationN/A
ENDRA Life Sciences
Price$6.54
Change+$1.00 (+18.05%)
Volume$750
CapitalizationN/A
LAB vs NDRA Comparison Chart
Loading...
LAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NDRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LAB vs. NDRA commentary
Dec 28, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LAB is a Hold and NDRA is a Buy.

Ad is loading...
COMPARISON
Comparison
Dec 28, 2024
Stock price -- (LAB: $1.90 vs. NDRA: $5.54)
Brand notoriety: LAB and NDRA are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: LAB: 31% vs. NDRA: 3%
Market capitalization -- LAB: $1.04B vs. NDRA: $4.44M
LAB [@Medical Specialties] is valued at $1.04B. NDRA’s [@Medical Specialties] market capitalization is $4.44M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LAB’s FA Score shows that 0 FA rating(s) are green whileNDRA’s FA Score has 0 green FA rating(s).

  • LAB’s FA Score: 0 green, 5 red.
  • NDRA’s FA Score: 0 green, 5 red.
According to our system of comparison, LAB is a better buy in the long-term than NDRA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LAB’s TA Score shows that 5 TA indicator(s) are bullish while NDRA’s TA Score has 4 bullish TA indicator(s).

  • LAB’s TA Score: 5 bullish, 5 bearish.
  • NDRA’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, NDRA is a better buy in the short-term than LAB.

Price Growth

LAB (@Medical Specialties) experienced а -4.28% price change this week, while NDRA (@Medical Specialties) price change was +3.17% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +2.48%. For the same industry, the average monthly price growth was -0.58%, and the average quarterly price growth was +3.34%.

Reported Earning Dates

LAB is expected to report earnings on Feb 12, 2025.

NDRA is expected to report earnings on May 15, 2023.

Industries' Descriptions

@Medical Specialties (+2.48% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LAB($1.04B) has a higher market cap than NDRA($4.44M). LAB YTD gains are higher at: -14.027 vs. NDRA (-99.851). NDRA has higher annual earnings (EBITDA): -12.09M vs. LAB (-54.46M). LAB has more cash in the bank: 115M vs. NDRA (3.34M). NDRA has less debt than LAB: NDRA (434K) vs LAB (98.2M). LAB has higher revenues than NDRA: LAB (106M) vs NDRA (0).
LABNDRALAB / NDRA
Capitalization1.04B4.44M23,323%
EBITDA-54.46M-12.09M450%
Gain YTD-14.027-99.85114%
P/E RatioN/AN/A-
Revenue106M0-
Total Cash115M3.34M3,448%
Total Debt98.2M434K22,627%
FUNDAMENTALS RATINGS
LAB vs NDRA: Fundamental Ratings
LAB
NDRA
OUTLOOK RATING
1..100
8511
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
61
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
4765
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5020

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LAB's Valuation (34) in the Medical Specialties industry is in the same range as NDRA (61) in the Biotechnology industry. This means that LAB’s stock grew similarly to NDRA’s over the last 12 months.

LAB's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as NDRA (100) in the Biotechnology industry. This means that LAB’s stock grew similarly to NDRA’s over the last 12 months.

LAB's SMR Rating (98) in the Medical Specialties industry is in the same range as NDRA (99) in the Biotechnology industry. This means that LAB’s stock grew similarly to NDRA’s over the last 12 months.

LAB's Price Growth Rating (47) in the Medical Specialties industry is in the same range as NDRA (65) in the Biotechnology industry. This means that LAB’s stock grew similarly to NDRA’s over the last 12 months.

LAB's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as NDRA (100) in the Biotechnology industry. This means that LAB’s stock grew similarly to NDRA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LABNDRA
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 5 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 11 days ago
81%
Bullish Trend 5 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 15 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
LAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NDRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ARQQ43.8314.70
+50.46%
Arqit Quantum Inc
TRNR2.900.03
+1.09%
Interactive Strength Inc
AEG5.870.03
+0.51%
Aegon Ltd
SFNC22.580.08
+0.36%
Simmons First National Corp
PKST11.17-0.09
-0.80%
Peakstone Realty Trust

NDRA and

Correlation & Price change

A.I.dvisor tells us that NDRA and ICUI have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NDRA and ICUI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NDRA
1D Price
Change %
NDRA100%
+3.44%
ICUI - NDRA
24%
Poorly correlated
-0.27%
CNMD - NDRA
23%
Poorly correlated
+1.24%
LAB - NDRA
22%
Poorly correlated
+3.83%
NVRO - NDRA
22%
Poorly correlated
+2.02%
PSNL - NDRA
22%
Poorly correlated
+2.79%
More